Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines

Group 1: COVID-19 Vaccines Update - The FDA has approved updated mRNA-based vaccines from Pfizer and Moderna to address new COVID-19 strains, particularly targeting the KP.2 strain [2][3] - The KP.2 strain was dominant in May but now accounts for approximately 3% of U.S. cases, while KP.3 and its related strain KP.3.1.1 account for nearly 17% and almost 37% of cases, respectively [3] - The updated vaccines are expected to produce stronger immune responses against circulating variants compared to last year's vaccines [2] Group 2: Eligibility and Availability - The CDC recommends that everyone aged 6 months and older receive one dose of the new COVID-19 vaccine, with a suggested waiting period of two to three months since the last vaccination or infection [4] - Vaccination appointments are available at pharmacies, hospitals, and clinics, with Walgreens and CVS already scheduling appointments for early September [5][6] Group 3: Cost and Access - Most private insurance plans, as well as Medicare and Medicaid, cover the cost of COVID-19 vaccinations, while a federally-funded program provides free shots for children [8] - The CDC has allocated $62 million for state and local immunization programs to cover costs for uninsured and underinsured adults [8] Group 4: Novavax Vaccine - Novavax has filed for authorization of a new protein-based vaccine targeting the JN.1 strain, which is expected to provide protection against its descendants [9]